Solu Therapeutics to Present Promising Research on STX-0712 at ASH Annual Meeting in Orlando Solu Therapeutics will unveil significant findings from its Phase 1 trial of STX-0712, targeting chronic myelomonocytic leukemia and acute myeloid leukemia at the ASH Annual Meeting.

Solu Therapeutics to Present Promising Research on STX-0712 at ASH Annual Meeting in Orlando #United_States #Orlando #Hematology #Solu_Therapeutics #STX-0712

Solu Therapeutics Welcomes Enda Moran as New COO to Propel Innovative Therapies Forward Solu Therapeutics announces the appointment of Dr. Enda Moran as COO, aiming to enhance its innovative therapies targeting cancer and immunology.

Solu Therapeutics Welcomes Enda Moran as New COO to Propel Innovative Therapies Forward #United_States #Boston #cancer_therapies #Solu_Therapeutics #Enda_Moran

Solu Therapeutics Secures $41 Million Series A Funding and Begins Phase 1 Trial of Innovative Cancer Treatment Solu Therapeutics has successfully completed a $41 million Series A financing. They also initiated the first patient dose in a Phase 1 trial of STX-0712 for hematologic malignancies.

Solu Therapeutics Secures $41 Million Series A Funding and Begins Phase 1 Trial of Innovative Cancer Treatment #United_States #Boston #Solu_Therapeutics #STX-0712 #CMML

Solu Therapeutics Showcases Encouraging Preclinical Findings for STX-0712 at the ASH Annual Meeting in San Diego At the ASH Annual Meeting, Solu Therapeutics unveiled promising preclinical results for STX-0712 targeting chronic myelomonocytic leukemia and acute myeloid leukemia.

Solu Therapeutics Showcases Encouraging Preclinical Findings for STX-0712 at the ASH Annual Meeting in San Diego #United_States #San_Diego #Solu_Therapeutics #STX-0712 #CMML

Solu Therapeutics Unveils Innovative Preclinical Data on STX-0712 for Leukaemia Treatment Discover how Solu Therapeutics is pioneering cancer therapies with STX-0712 targeting chronic myelomonocytic leukaemia and acute myeloid leukaemia at the ASH Conference.

Solu Therapeutics Unveils Innovative Preclinical Data on STX-0712 for Leukaemia Treatment #USA #San_Diego #Leukemia #Solu_Therapeutics #STX-0712